Program
PG4
Its studies are mostly in Pneumococcal Infections, led by Pfizer.
Furthest: phase 3, since Apr 30, 20265 company-led studies, 4 open or runningNext primary completion: Mar 4, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 54 open or running | phase 3since Apr 30, 2026 | Jul 23, 2024 | Mar 4, 2027phase 2 · NCT06524414 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2024First studies: 2 phase 2 studies in Pneumococcal InfectionsFirst studyNCT06531538, NCT06524414
- Apr 30, 2026Phase 3 study in Pneumococcal InfectionsPhase 3 reachedNCT07573462 · 2,400 planned · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in Pneumococcal InfectionsNCT07629440 · 3,230 planned · United States, Japan, Puerto Rico
- Jun 15, 2026Phase 3 study in Pneumococcal InfectionsNCT07660198 · 1,200 planned · United States, Finland, Poland and more
Ahead
- Mar 4, 2027Primary completion: phase 2 study in Pneumococcal InfectionsNCT06524414
- Dec 2, 2027Primary completion: phase 3 study in Pneumococcal InfectionsNCT07660198
- Dec 30, 2028Primary completion: phase 3 study in Pneumococcal InfectionsNCT07573462
- Jun 5, 2029Primary completion: phase 3 study in Pneumococcal InfectionsNCT07629440
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660198Pneumococcal Infections · United States, Finland, Poland and more | 3 | Recruiting | Dec 2, 2027 | 1,200 |
| NCT07629440Pneumococcal Infections · United States, Japan, Puerto Rico | 3 | Recruiting | Jun 5, 2029 | 3,230 |
| NCT07573462Pneumococcal Infections · United States, Argentina, Australia and more | 3 | Recruiting | Dec 30, 2028 | 2,400 |
| NCT06531538Pneumococcal Infections · United States, Puerto Rico | 2 | Completed | Feb 9, 2026 | 225 |
| NCT06524414Pneumococcal Infections · United States, Puerto Rico | 2 | Active, not recruiting | Mar 4, 2027 | 605 |
How it is read
Names in the registry
- “PG4”, 5 entries
Conditions, from the studies’ own filings
- Pneumococcal Infections, 5 studies
First seen by our ledger Nov 14, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.